# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-23-001633
**Filing Date:** 2023-2
**Character Count:** 42345
**Document Hash:** 0f416a75a7fc280fa9cf03e3e07b9ea1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-001633.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001654954-23-001633

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230214

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK PLC
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 23622199

**BUSINESS ADDRESS:**
- **STREET 1:** 980 GREAT WEST ROAD
- **CITY:** BRENTFORD MIDDLESEX
- **STATE:** X0
- **ZIP:** TW8 9GS
- **BUSINESS PHONE:** 011442080475000

**MAIL ADDRESS:**
- **STREET 1:** 980 GREAT WEST ROAD
- **CITY:** BRENTFORD MIDDLESEX
- **STATE:** X0
- **ZIP:** TW8 9GS

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February 2023

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **980 Great West Road, Brentford, Middlesex, TW8 9GS**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GSK plc **(the 'Company')**

 **Deferred Annual Bonus Plan Awards**

On 9 February 2023, the Company granted awards to the Persons Discharging Managerial Responsibilities ('PDMRs') listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') which was approved by shareholders on 4 May 2017.

Executive Directors and other members of the GSK Leadership Team are required to defer part of any bonus earned into Ordinary Shares or American Depositary Shares ('ADSs') for three years. Under the terms of the Remuneration Policy approved by shareholders in 2022, Executive Directors are required to defer 50% of bonus equivalent of the first 200% of salary with any portion in excess of 200% being deferred in full. Other members of the GSK Leadership Team are required to defer 25% of bonus equivalent of the first 170% of salary into Ordinary Shares or ADSs with any portion in excess of 170% being deferred in full.

The awards have been granted as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.

The numbers of Ordinary Shares and ADSs shown below are exclusive of dividend reinvestment that will accrue during the deferral period.

Transaction notification

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Ms E Walmsley | Ms E Walmsley |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | Chief Executive Officer | Chief Executive Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 125482 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Mr I Mackay | Mr I Mackay |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | Chief Financial Officer | Chief Financial Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 77751 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Ms D Conrad | Ms D Conrad |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | Chief People Officer | Chief People Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 22842 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Mr J Ford | Mr J Ford |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | SVP and Group General Counsel, Legal and Compliance | SVP and Group General Counsel, Legal and Compliance |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 22223 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Ms S Jackson | Ms S Jackson |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | SVP, Global Communications and CEO Office | SVP, Global Communications and CEO Office |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010<br>| 13830 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Mr L Miels | Mr L Miels |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | Chief Commercial Officer | Chief Commercial Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 53528 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Ms S Ramakrishnan | Ms S Ramakrishnan |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | Chief Digital and Technology Officer | Chief Digital and Technology Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | American Depositary Shares ('ADSs')<br>ISIN: US37733W2044 | American Depositary Shares ('ADSs')<br>ISIN: US37733W2044 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | $36.320 | 11145 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Mr D Redfern | Mr D Redfern |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | President Corporate Development | President Corporate Development |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 30942 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Mr R Simard | Mr R Simard |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | President, Global Supply Chain | President, Global Supply Chain |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 24852 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Mr P Thomson | Mr P Thomson |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | President, Global Affairs | President, Global Affairs |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 16260 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Ms D Waterhouse | Ms D Waterhouse |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | CEO, ViiV Healthcare and President, Global Health, GSK |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 39600 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** | &nbsp;&nbsp;&nbsp; **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | Dr T Wood | Dr T Wood |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Position/status | Chief Scientific Officer | Chief Scientific Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | &nbsp;&nbsp;&nbsp; **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | &nbsp;&nbsp;&nbsp; **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | &nbsp;&nbsp;&nbsp; Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | &nbsp;&nbsp;&nbsp; Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | Price(s) | Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) | £15.010 | 18792 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | &nbsp;&nbsp;&nbsp; Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated information | N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | &nbsp;&nbsp;&nbsp; Aggregated volume Price |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | &nbsp;&nbsp;&nbsp; Date of the transaction | 2023-02-09 | 2023-02-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | &nbsp;&nbsp;&nbsp; Place of the transaction<br>| N/A | N/A |

---

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: February 14, 2023 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---